NASDAQ: ORMPOramed Pharmaceuticals Inc Stock
$2.35+0.04 (+1.73%)
Updated Sep 6, 2024
ORMP Price
$2.35
Fair Value Price
$0.22
Market Cap
$95.81M
52 Week Low
$1.67
52 Week High
$3.67
P/E
4.61x
P/B
0.54x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
$20.86M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.05
Operating Cash Flow
-$2M
Beta
0.94
Next Earnings
Nov 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A
ORMP Overview
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ORMP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ORMP ($2.35) is overvalued by 962.95% relative to our estimate of its Fair Value price of $0.22 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ORMP ($2.35) is not significantly undervalued (962.95%) relative to our estimate of its Fair Value price of $0.22 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ORMP is forecast by analysts... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ORMP due diligence checks available for Premium users.
Be the first to know about important ORMP news, forecast changes, insider trades & much more!
ORMP News
Valuation
ORMP fair value
Fair Value of ORMP stock based on Discounted Cash Flow (DCF)
Price
$2.35
Fair Value
$0.22
Overvalued by
962.95%
ORMP ($2.35) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ORMP ($2.35) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ORMP is forecast by analysts... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ORMP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
4.61x
Industry
-46.85x
Market
24.57x
ORMP is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ORMP is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
ORMP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.54x
Industry
6.22x
ORMP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ORMP's financial health
Profit margin
Revenue
$0.0
Net Income
$9.2M
Profit Margin
0%
ORMP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$184.2M
Liabilities
$8.1M
Debt to equity
0.05
ORMP's short-term assets ($153.27M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ORMP's short-term assets ($153.27M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ORMP's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ORMP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$2.1M
Investing
$94.7M
Financing
-$30.6M
ORMP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ORMP vs Biotech Stocks
Oramed Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.